2376. In Vitro Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Collected from Patients with Skin and Skin Structure Infections in Latin America: AWARE Surveillance Program 2017
Session: Poster Abstract Session: Skin and Skin Structure Infection
Saturday, October 6, 2018
Room: S Poster Hall
Posters
  • Pfizer_P67_CPT vs SSTI LA 2017_IDSA 2018_FINAL.pdf (211.5 kB)
  • Background: The parenteral cephem ceftaroline (CPT) fosamil is approved for the treatment of patients with skin and skin structure infections (SSSIs) caused by Staphylococcus aureus (both methicillin-susceptible [MSSA] and methicillin-resistant [MRSA] isolates), β-hemolytic streptococci (Streptococcus pyogenes, Streptococcus agalactiae), and select species of Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca). Limited data have been published on the in vitro activity of CPT against recent clinical isolates cultured from patients with SSSIs in Latin America (LA).

    Methods: Standard CLSI broth microdilution MIC determinations (M07) were performed with CPT and comparator agents. MICs were interpreted using current CLSI M100 MIC breakpoints. Clinically relevant, non-duplicate, isolates cultured from patients with SSSIs in 6 countries in LA in 2017 were tested by the AWARE Surveillance Program central laboratory (IHMA). In total, 1,435 non-duplicate isolates of MSSA, MRSA, β-hemolytic streptococci, and Enterobacteriaceae were tested: Argentina (n = 349/24.3% of all isolates tested), Brazil (114/7.9%), Chile (153/10.7%), Columbia (175/12.2%), Mexico (339/23.6%), and Venezuela (305/21.3%).

    Results:

    CPT activity is summarized in the following table.

    CPT MIC Breakpoints (µg/ml)

    CPT MIC (µg/ml)

    CPT MIC Interpretation

    Bacteria

    n

    S | I | R

    MIC50

    MIC90

    % S

    % I

    % R

    MSSA

    354

    ≤1 | 2 | ≥4

    0.25

    0.5

    100

    0

    0

    MRSA

    389

    ≤1 | 2 | ≥4

    0.5

    1

    95.1

    4.9

    0

    β-hemolytic streptococcia

    130

    ≤0.5 | − | −

    0.008

    0.015

    100

    Enterobacteriaceae, All

    562

    ≤0.5 | 1 | ≥2

    0.5

    >128

    55.3

    3.9

    40.8

    Enterobacteriaceae, ESBL screen-negative

    358

    ≤0.5 | 1 | ≥2

    0.12

    1

    86.6

    5.9

    7.5

    a S. pyogenes (n=90), S. agalactiae (n=26), and S. dysgalactiae (n=14).

    Conclusion: Overall, 100% of MSSA and 95.1% of MRSA from LA were susceptible to CPT (MIC ≤1 µg/ml); 19 isolates of MRSA were CPT-intermediate (MIC 2 µg/ml) with 17 of the 19 isolates being from Chile; no CPT-resistant MRSA were observed. All β-hemolytic streptococci and 86.6% of ESBL-negative Enterobacteriaceae were also susceptible to CPT. CPT continues to demonstrate potent in vitro activity against clinically relevant pathogens associated with SSSIs for patients in LA.

    Meredith Hackel, Ph.D1, James Karlowsky, PhD, D(ABMM), F(AAM)1, Dan Sahm, PhD2 and Gregory G. Stone, Ph.D.3, (1)IHMA, Inc., Schaumburg, IL, (2)International Health Management Associates, Inc., Schaumburg, IL, (3)Pfizer, Inc., New York, NY

    Disclosures:

    M. Hackel, Pfizer Inc.: Consultant , Consulting fee . IHMA, Inc.: Employee , Salary .

    J. Karlowsky, IHMA, Inc.: Consultant , Consulting fee .

    D. Sahm, Pfizer Inc.: Consultant , Consulting fee . IHMA, Inc.: Employee , Salary .

    G. G. Stone, Pfizer Inc.: Employee , Salary . AstraZeneca: Former Employee and Shareholder , Salary .

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.